Ligand granted Hainan Kaihua's Chiva affiliate rights in China to develop and commercialize Pradefovir for HBV and MB01733 for liver cancer, plus a non-exclusive license to HepDirect

Ligand Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Hainan Kaihua Pharmaceutical Co. Ltd.

China / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced